Tandem Diabetes Care Announces Issuance of Patent Related to Remote Bolus Feature for Medical Infusion Pumps
August 24 2017 - 4:05PM
Business Wire
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device
company and manufacturer of the only touchscreen insulin pumps
available in the United States, today announced the issuance of
U.S. Patent No. 9,737,656 titled “Integration of Infusion Pump with
Remote Electronic Device”. The patent generally relates to using a
software application operating on a remote consumer electronic
device to initiate, program and deliver a medicament bolus to a
patient using a medical infusion pump where the pump provides an
indication of the bolus, such as by an audible or vibration
alert.
“The operation of an insulin pump using a consumer electronic
device, such as a smart phone, is a top area of interest in our
next generation pump development efforts,“ said Kim Blickenstaff,
President and Chief Executive Officer of Tandem Diabetes Care. “As
the only Company with experience in the use of touchscreen insulin
pump control, we are uniquely positioned to identify new and novel
ways to safely utilize the computing power of our everyday consumer
devices to operate a life-sustaining infusion pump. This patent
reflects our foresight to integrate consumer and medical device
technologies to further our mission to simplify the lives of people
with diabetes and covers key features we believe will be beneficial
for commercial adoption in the future.”
U.S. Patent No. 9,737,656 expires in 2035. The Company has a
related U.S. continuation application on file, as well as a pending
application in Europe.
This newly issued patent raises Tandem Diabetes Care’s patent
portfolio to 56 issued U.S. patents and 50 pending U.S. patent
applications. In addition, the Company has, and is seeking, patent
protection for proprietary technologies in other countries
throughout the world.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company with an innovative, user-centric and integrated
approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest
and smallest durable insulin pump currently on the market, the
t:flex® Insulin Pump, the first pump designed for people with
greater insulin requirements, and the t:slim G4™ Insulin Pump, the
first continuous glucose monitoring-enabled pump with touch-screen
simplicity. Tandem is based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use
#tslimX2, #tslimG4, #tflex, #tconnect, and $TNDM.Follow Tandem
Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.Follow
Tandem Diabetes Care on LinkedIn at
https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care, t:connect and t:flex are registered
trademarks, and t:slim X2 and t:slim G4 are trademarks of Tandem
Diabetes Care, Inc. All other trademarks are the property of their
respective owners.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that concern matters that involve risks and uncertainties
that could cause actual results to differ materially from those
anticipated or projected in the forward-looking statements. These
forward-looking statements relate to, among other things the scope
and enforceability of the company’s intellectual property,
including the expected expiration of the 9,737,656 patent, and
whether the technology referenced in this patent will beneficial
for commercial adoption in the future. Many factors could cause the
company’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements that may be expressed or implied by such
forward-looking statements, including without limitation, those
listed under the heading “Risk Factors” in the company’s most
recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q
and other documents that Tandem files with the Securities and
Exchange Commission. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this release. Tandem undertakes no obligation to
update or review any forward-looking statement in this press
release because of new information, future events or other
factors.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170824006117/en/
Tandem Diabetes Care, Inc.Media Contact:Steve Sabicer,
714-907-6264ssabicer@thesabicergroup.comorInvestor
Contact:Susan Morrison, 858-366-6900
x7005smorrison@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Sep 2023 to Sep 2024